Detalhe da pesquisa
1.
Long-term outcomes with biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in ST-segment elevation myocardial infarction: 5-year follow-up of the BIOSTEMI randomised superiority trial.
Lancet
; 402(10416): 1979-1990, 2023 11 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-37898137
2.
Ultrathin-strut vs thin-strut drug-eluting stents for multi and single-stent lesions: A lesion-level subgroup analysis of 2 randomized trials.
Am Heart J
; 263: 73-84, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37192697
3.
Complex primary percutaneous coronary intervention with ultrathin-strut biodegradable versus thin-strut durable polymer drug-eluting stents in patients with ST-segment elevation myocardial infarction: A subgroup analysis from the BIOSTEMI randomized trial.
Catheter Cardiovasc Interv
; 101(4): 687-700, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36807456
4.
Biodegradable polymer sirolimus-eluting stents vs durable polymer everolimus-eluting stents in patients undergoing percutaneous coronary intervention: A meta-analysis of individual patient data from 5 randomized trials.
Am Heart J
; 235: 140-148, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33609498
5.
Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial.
Lancet
; 394(10205): 1243-1253, 2019 10 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31488372
6.
Ultrathin-strut, biodegradable-polymer, sirolimus-eluting stents versus thin-strut, durable-polymer, everolimus-eluting stents for percutaneous coronary revascularisation: 5-year outcomes of the BIOSCIENCE randomised trial.
Lancet
; 392(10149): 737-746, 2018 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30170848
7.
Everolimus-eluting bioresorbable stent vs. durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: results of the randomized ABSORB ST-segment elevation myocardial infarction-TROFI II trial.
Eur Heart J
; 37(3): 229-40, 2016 Jan 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-26405232
8.
Biodegradable-polymer stents versus durable-polymer stents - Authors' reply.
Lancet
; 393(10184): 1933, 2019 05 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31084961
9.
Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial.
Lancet
; 384(9960): 2111-22, 2014 Dec 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-25189359
10.
Five-Year Outcomes With Biodegradable-Polymer Sirolimus-Eluting Stents Versus Durable-Polymer Everolimus-Eluting Stents in Patients With Acute Coronary Syndrome: A Subgroup Analysis of the BIOSCIENCE Trial.
Cardiovasc Revasc Med
; 34: 3-10, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33653633
11.
Clinical outcomes following transcatheter aortic valve implantation in patients with porcelain aorta.
J Cardiovasc Comput Tomogr
; 16(3): 215-221, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-34756819
12.
Magmaris Resorbable Magnesium Scaffold Versus Conventional Drug-Eluting Stent in ST-Segment Elevation Myocardial Infarction: 1-Year Results of a Propensity-Score-Matching Comparison.
Cardiovasc Revasc Med
; 43: 28-35, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35641364
13.
Multivessel percutaneous coronary intervention with thin-strut biodegradable versus durable polymer drug-eluting stents in ST-segment elevation myocardial infarction: A subgroup analysis of the BIOSTEMI randomized trial.
Int J Cardiol
; 334: 37-41, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33887341
14.
Biodegradable- Versus Durable-Polymer Drug-Eluting Stents for STEMI: Final 2-Year Outcomes of the BIOSTEMI Trial.
JACC Cardiovasc Interv
; 14(6): 639-648, 2021 03 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-33727005
15.
Five-Year Outcomes in Patients With Diabetes Mellitus Treated With Biodegradable Polymer Sirolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents.
J Am Heart Assoc
; 8(22): e013607, 2019 11 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-31696762
16.
Everolimus-Eluting Biodegradable Polymer Versus Everolimus-Eluting Durable Polymer Stent for Coronary Revascularization in Routine Clinical Practice.
JACC Cardiovasc Interv
; 12(17): 1665-1675, 2019 09 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31422088
17.
Sheathless Transcaval Transcatheter Aortic Valve Implantation Through an Abdominal Aortic Graft.
Can J Cardiol
; 34(12): 1688.e17-1688.e19, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30527166
18.
Unselected Use of Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent for Coronary Revascularization.
Circ Cardiovasc Interv
; 11(9): e006741, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30354590
19.
A comparison of an ultrathin-strut biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent for patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: rationale and design of the BIOSTEMI trial.
EuroIntervention
; 14(6): 692-699, 2018 Aug 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-29205157
20.
Orsiro cobalt-chromium sirolimus-eluting stent: present and future perspectives.
Expert Rev Med Devices
; 14(10): 773-788, 2017 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-28889769